Top

Endocrine

Published in:

01-11-2017 | Original Article

Safety of transsphenoidal microsurgical approach in patients with an ACTH-secreting pituitary adenoma

Authors: Carmine Antonio Donofrio, Marco Losa, Marco Gemma, Lodoviga Giudice, Lina Raffaella Barzaghi, Pietro Mortini

Published in: Endocrine | Issue 2/2017

Abstract

Purpose

Patients affected by Cushing’s disease often have important comorbidities directly linked to hypercortisolism that might enhance the operative risk. We report the safety of transsphenoidal surgery in patients affected by Cushing’s disease as compared with patients with nonfunctioning pituitary adenoma.

Methods

We have retrospectively analyzed 142 patients with Cushing’s disease and 299 patients with nonfunctioning pituitary adenoma who underwent transsphenoidal surgery performed by a single experienced neurosurgeon between September 2007 and December 2014. For all of them, an intraoperative computerized anesthetic record for the automatic storage of data was available.

Results

The intraoperative vital parameters and the frequency of drugs administered during anesthesia were comparable between Cushing’s disease and nonfunctioning pituitary adenoma groups. The duration of surgery was similar between the two groups (41.2 ± 11.8 vs. 42.9 ± 15.6 min), while the duration of anesthesia was slightly shorter in Cushing’s disease patients (97.6 ± 18.1 min) than in nonfunctioning pituitary adenoma patients (101.6 ± 20.6 min, p = 0.04). The total perioperative mortality rate was 0.2% (0% in Cushing’s disease vs. 0.3% in nonfunctioning pituitary adenoma). Cushing’s disease patients had surgical and medical complication rates of 3.5% each, not different from those occurring in nonfunctioning pituitary adenoma. The postoperative incidence of diabetes insipidus (10.6%) and isolated hyponatremia (10.6%) in Cushing’s disease patients was significantly higher than in nonfunctioning pituitary adenoma patients (4.4 and 4.1%; p = 0.02 and p = 0.01, respectively).

Conclusions

In a large series of unselected and consecutive patients with Cushing’s disease, transsphenoidal surgery performed by one dedicated experienced neurosurgeon had a reasonably low risk of complications. In particular, despite the higher burden of comorbidities typically associated with hypercortisolism, medical complications are rare and no more frequent than in patients with nonfunctioning pituitary adenoma.

Available only for authorised users

C. Steffensen, A.M. Bak, K.Z. Rubeck, J.O. Jorgensen, Epidemiology of cushing’s syndrome. Neuroendocrinology 92(Suppl 1), 1–5 (2010). doi:10.1159/000314297 CrossRefPubMed

M. Losa, P. Mortini, S. Dylgjeri, R. Barzaghi, A. Franzin, C. Mandelli, M. Giovanelli, Desmopressin stimulation test before and after pituitary surgery in patients with cushing’s disease. Clin. Endocrinol. 55(1), 61–68 (2001)CrossRef

P. Mortini, M. Losa, R. Barzaghi, N. Boari, M. Giovanelli, Results of transsphenoidal surgery in a large series of patients with pituitary Adenoma. Neurosurgery 56(6), 1222–1233 (2005). doi:10.1227/01.neu.0000159647.64275.9d CrossRefPubMed

B.M. Biller, A.B. Grossman, P.M. Stewart, S. Melmed, X. Bertagna, J. Bertherat, M. Buchfelder, A. Colao, A.R. Hermus, L.J. Hofland, A. Klibanski, A. Lacroix, J.R. Lindsay, J. Newell-Price, L.K. Nieman, S. Petersenn, N. Sonino, G.K. Stalla, B. Swearingen, M.L. Vance, J.A. Wass, M. Boscaro, Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J. Clin Endocrinol. Metab. 93(7), 2454–2462 (2008). doi:10.1210/jc.2007-2734 CrossRefPubMedPubMedCentral

N.A. Tritos, B.M. Biller, B. Swearingen, Management of cushing disease. Nat. Rev. Endocrinol. 7(5), 279–289 (2011). doi:10.1038/nrendo.2011.12 CrossRefPubMed

R. Pivonello, M. De Leo, A. Cozzolino, A. Colao, The treatment of cushing’s disease. Endocr. Rev. 36(4), 385–486 (2015). doi:10.1210/er.2013-1048 CrossRefPubMedPubMedCentral

R.R. Lonser, L. Nieman, E.H. Oldfield, Cushing’s disease: pathobiology, diagnosis, and management. J. Neurosurg. 1–14 (2016). 10.3171/2016.1.JNS152119

F.G. Barker 2nd, A. Klibanski, B. Swearingen, Transsphenoidal surgery for pituitary tumors in the United States, 1996–2000: mortality, morbidity, and the effects of hospital and surgeon volume. J. Clin. Endocrinol. Metab. 88(10), 4709–4719 (2003). doi:10.1210/jc.2003-030461 CrossRefPubMed

L.R. Barzaghi, M. Losa, M. Giovanelli, P. Mortini, Complications of transsphenoidal surgery in patients with pituitary adenoma: experience at a single centre. Acta. Neurochir. 149(9), 877–886 (2007). doi:10.1007/s00701-007-1244-8 CrossRefPubMed

10.

I. Ciric, A. Ragin, C. Baumgartner, D. Pierce, Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 40(2), 225–237 (1997)CrossRefPubMed

11.

A.N. Mamelak, Pro: endoscopic endonasal transsphenoidal pituitary surgery is superior to microscope-based transsphenoidal surgery. Endocrine 47(2), 409–414 (2014). doi:10.1007/s12020-014-0294-y CrossRefPubMed

12.

P. Mortini, Cons: endoscopic endonasal transsphenoidal pituitary surgery is not superior to microscopic transsphenoidal surgery for pituitary adenomas. Endocrine 47(2), 415–420 (2014). doi:10.1007/s12020-014-0365-0 CrossRefPubMed

13.

A.L. Utz, B. Swearingen, B.M. Biller, Pituitary surgery and postoperative management in Cushing’s disease. Endocrinol. Metab. Clin. North. Am. 34(2), 459–478 (2005). doi:10.1016/j.ecl.2005.01.007. xiCrossRefPubMed

14.

R. Domi, Cushing’s surgery: role of the anesthesiologist. Indian. J. Endocrinol. Metab. 15(Suppl 4), S322–328 (2011). doi:10.4103/2230-8210.86975 CrossRefPubMedPubMedCentral

15.

S. Cannavo, E. Messina, A. Albani, F. Ferrau, V. Barresi, S. Priola, F. Esposito, F. Angileri, Clinical management of critically ill patients with cushing’s disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide. Endocrine 52(3), 481–487 (2016). doi:10.1007/s12020-015-0601-2 CrossRefPubMed

16.

F. Castinetti, I. Morange, P. Jaquet, B. Conte-Devolx, T. Brue, Ketoconazole revisited: a preoperative or postoperative treatment in cushing’s disease. Eur. J. Endocrinol. 158(1), 91–99 (2008). doi:10.1530/EJE-07-0514 CrossRefPubMed

17.

V.A. Preda, J. Sen, N. Karavitaki, A.B. Grossman, Etomidate in the management of hypercortisolaemia in cushing’s syndrome: a review. Eur. J. Endocrinol. 167(2), 137–143 (2012). doi:10.1530/EJE-12-0274 PubMed

18.

P. Kamenicky, C. Droumaguet, S. Salenave, A. Blanchard, C. Jublanc, J.F. Gautier, S. Brailly-Tabard, S. Leboulleux, M. Schlumberger, E. Baudin, P. Chanson, J. Young, Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent cushing’s syndrome. J. Clin. Endocrinol. Metab. 96(9), 2796–2804 (2011). doi:10.1210/jc.2011-0536 CrossRefPubMed

19.

K. McKeage, Pasireotide: a review of its use in cushing’s disease. Drugs 73(6), 563–574 (2013). doi:10.1007/s40265-013-0052-0 CrossRefPubMed

20.

M.R. Gadelha, L. Vieira Neto, Efficacy of medical treatment in cushing’s disease: a systematic review. Clin. Endocrinol. 80(1), 1–12 (2014). doi:10.1111/cen.12345 CrossRef

21.

O.F. van den Bosch, A.M. Stades, P.M. Zelissen, Increased long-term remission after adequate medical cortisol suppression therapy as presurgical treatment in cushing’s disease. Clin. Endocrinol. 80(2), 184–190 (2014). doi:10.1111/cen.12286 CrossRef

22.

M. Losa, C.A. Donofrio, R. Barzaghi, P. Mortini, Presentation and surgical results of incidentally discovered nonfunctioning pituitary adenomas: evidence for a better outcome independently of other patients’ characteristics. Eur. J. Endocrinol. 169(6), 735–742 (2013). doi:10.1530/EJE-13-0515 CrossRefPubMed

23.

M. Gemma, C. Tommasino, S. Cozzi, S. Narcisi, P. Mortini, M. Losa, A. Soldarini, Remifentanil provides hemodynamic stability and faster awakening time in transsphenoidal surgery. Anesth. Analg. 94(1), 163–168 (2002)PubMed

24.

P. Mortini, R. Barzaghi, M. Losa, N. Boari, M. Giovanelli, Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients. Neurosurgery 60(6), 993–1004 (2007). doi:10.1227/01.NEU.0000255459.14764.BA CrossRefPubMed

25.

M. Ammirati, L. Wei, I. Ciric, Short-term outcome of endoscopic versus microscopic pituitary adenoma surgery: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 84(8), 843–849 (2013). doi:10.1136/jnnp-2012-303194 CrossRefPubMed

26.

T.J. Mampalam, J.B. Tyrrell, C.B. Wilson, Transsphenoidal microsurgery for cushing disease. A report of 216 cases. Ann. Intern. Med. 109(6), 487–493 (1988)CrossRefPubMed

27.

D. Bochicchio, M. Losa, M. Buchfelder, Factors influencing the immediate and late outcome of cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European cushing’s disease survey group. J. Clin. Endocrinol. Metab. 80(11), 3114–3120 (1995). doi:10.1210/jcem.80.11.7593411 PubMed

28.

U.J. Knappe, D.K. Ludecke, Persistent and recurrent hypercortisolism after transsphenoidal surgery for cushing’s disease. Acta. Neurochir. Suppl. 65, 31–34 (1996)PubMed

29.

C. Invitti, F. Pecori Giraldi, M. de Martin, F. Cavagnini, Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. Study group of the Italian society of endocrinology on the pathophysiology of the hypothalamic-pituitary-adrenal axis. J. Clin. Endocrinol. Metab. 84(2), 440–448 (1999). doi:10.1210/jcem.84.2.5465 PubMed

30.

G.D. Hammer, J.B. Tyrrell, K.R. Lamborn, C.B. Applebury, E.T. Hannegan, S. Bell, R. Rahl, A. Lu, C.B. Wilson, Transsphenoidal microsurgery for cushing’s disease: initial outcome and long-term results. J. Clin. Endocrinol. Metab. 89(12), 6348–6357 (2004). doi:10.1210/jc.2003-032180 CrossRefPubMed

31.

C.G. Patil, D.M. Prevedello, S.P. Lad, M.L. Vance, M.O. Thorner, L. Katznelson, E.R. Laws Jr., Late recurrences of Cushing’s disease after initial successful transsphenoidal surgery. J. Clin. Endocrinol. Metab. 93(2), 358–362 (2008). doi:10.1210/jc.2007-2013 CrossRefPubMed

32.

B.M. Hofmann, M. Hlavac, R. Martinez, M. Buchfelder, O.A. Muller, R. Fahlbusch, Long-term results after microsurgery for cushing disease: experience with 426 primary operations over 35 years. J. Neurosurg. 108(1), 9–18 (2008). doi:10.3171/JNS/2008/108/01/0009 CrossRefPubMed

33.

J. Jagannathan, R. Smith, H.L. DeVroom, A.O. Vortmeyer, C.A. Stratakis, L.K. Nieman, E.H. Oldfield, Outcome of using the histological pseudocapsule as a surgical capsule in Cushing disease. J. Neurosurg. 111(3), 531–539 (2009). doi:10.3171/2008.8.JNS08339 CrossRefPubMedPubMedCentral

34.

J.R. Lindsay, E.H. Oldfield, C.A. Stratakis, L.K. Nieman, The postoperative basal cortisol and CRH tests for prediction of long-term remission from Cushing’s disease after transsphenoidal surgery. J. Clin. Endocrinol. Metab. 96(7), 2057–2064 (2011). doi:10.1210/jc.2011-0456 CrossRefPubMedPubMedCentral

35.

J.K. Lambert, L. Goldberg, S. Fayngold, J. Kostadinov, K.D. Post, E.B. Geer, Predictors of mortality and long-term outcomes in treated cushing’s disease: a study of 346 patients. J. Clin. Endocrinol. Metab. 98(3), 1022–1030 (2013). doi:10.1210/jc.2012-2893 CrossRefPubMedPubMedCentral

36.

W.F. Chandler, A.L. Barkan, T. Hollon, A. Sakharova, J. Sack, B. Brahma, D.E. Schteingart, Outcome of transsphenoidal surgery for cushing disease: a single-center experience over 32 years. Neurosurgery 78(2), 216–223 (2016). doi:10.1227/NEU.0000000000001011 CrossRefPubMed

37.

R.A. Feelders, L.J. Hofland, W.W. de Herder, Medical treatment of cushing’s syndrome: adrenal-blocking drugs and ketaconazole. Neuroendocrinology 92(Suppl 1), 111–115 (2010). doi:10.1159/000314292 CrossRefPubMed

38.

P.L. Semple, E.R. Laws Jr., Complications in a contemporary series of patients who underwent transsphenoidal surgery for cushing’s disease. J. Neurosurg. 91(2), 175–179 (1999). doi:10.3171/jns.1999.91.2.0175 CrossRefPubMed

39.

P.F. Svider, M.D. Raikundalia, M.J. Pines, S. Baredes, A.J. Folbe, J.K. Liu, J.A. Eloy, Inpatient complications after transsphenoidal surgery in cushing’s versus non-cushing’s disease patients. Ann. Otol. Rhinol. Laryngol. 125(1), 5–11 (2016). doi:10.1177/0003489415595424 CrossRefPubMed

40.

R.A. Feelders, S.J. Pulgar, A. Kempel, A.M. Pereira, The burden of cushing’s disease: clinical and health-related quality of life aspects. Eur. J. Endocrinol. 167(3), 311–326 (2012). doi:10.1530/EJE-11-1095 CrossRefPubMed

41.

R.N. Clayton, D. Raskauskiene, R.C. Reulen, P.W. Jones, Mortality and morbidity in cushing’s disease over 50 years in stoke-on-trent, UK: audit and meta-analysis of literature. J. Clin. Endocrinol. Metab. 96(3), 632–642 (2011). doi:10.1210/jc.2010-1942 CrossRefPubMed

42.

S.T. Sharma, L.K. Nieman, R.A. Feelders, Comorbidities in cushing’s disease. Pituitary 18(2), 188–194 (2015). doi:10.1007/s11102-015-0645-6 CrossRefPubMedPubMedCentral

43.

E. Valassi, A. Santos, M. Yaneva, M. Toth, C.J. Strasburger, P. Chanson, J.A. Wass, O. Chabre, M. Pfeifer, R.A. Feelders, S. Tsagarakis, P.J. Trainer, H. Franz, K. Zopf, S. Zacharieva, S.W. Lamberts, A. Tabarin, S.M. Webb, E.S. Group, The European registry on cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur. J. Endocrinol. 165(3), 383–392 (2011). doi:10.1530/EJE-11-0272 CrossRefPubMed

44.

L. Trementino, G. Arnaldi, G. Appolloni, V. Daidone, C. Scaroni, A. Casonato, M. Boscaro, Coagulopathy in cushing’s syndrome. Neuroendocrinology 92(Suppl 1), 55–59 (2010). doi:10.1159/000314349 CrossRefPubMed

45.

M. Boscaro, N. Sonino, A. Scarda, L. Barzon, F. Fallo, M.T. Sartori, G.M. Patrassi, A. Girolami, Anticoagulant prophylaxis markedly reduces thromboembolic complications in cushing’s syndrome. J. Clin. Endocrinol. Metab. 87(8), 3662–3666 (2002). doi:10.1210/jcem.87.8.8703 PubMed

46.

R. van der Pas, F.W. Leebeek, L.J. Hofland, W.W. de Herder, R.A. Feelders, Hypercoagulability in cushing’s syndrome: prevalence, pathogenesis and treatment. Clin. Endocrinol. 78(4), 481–488 (2013). doi:10.1111/cen.12094 CrossRef

47.

R. Fahlbusch, M. Buchfelder, O.A. Muller, Transsphenoidal surgery for Cushing’s disease. J. R. Soc. Med. 79(5), 262–269 (1986)CrossRefPubMedPubMedCentral

48.

I. Ciric, J.C. Zhao, H. Du, J.W. Findling, M.E. Molitch, R.E. Weiss, S. Refetoff, W.D. Kerr, J. Meyer, Transsphenoidal surgery for cushing disease: experience with 136 patients. Neurosurgery 70(1), 70–81 (2012). doi:10.1227/NEU.0b013e31822dda2c CrossRefPubMedPubMedCentral

49.

T.R. Smith, M.M. Hulou, K.T. Huang, B. Nery, S.M. de Moura, D.J. Cote, E.R. Laws, Complications after transsphenoidal surgery for patients with cushing’s disease and silent corticotroph adenomas. Neurosurg. Focus. 38(2), E12 (2015). doi:10.3171/2014.10.FOCUS14705 CrossRefPubMed

50.

D. Wilson, D.L. Jin, T. Wen, J.D. Carmichael, S. Cen, W.J. Mack, G. Zada, Demographic factors, outcomes, and patient access to transsphenoidal surgery for cushing’s disease: analysis of the nationwide inpatient sample from 2002 to 2010. Neurosurg. Focus. 38(2), E2 (2015). doi:10.3171/2014.11.FOCUS14694 CrossRefPubMed

51.

B.R. Olson, D. Rubino, J. Gumowski, E.H. Oldfield, Isolated hyponatremia after transsphenoidal pituitary surgery. J. Clin. Endocrinol. Metab. 80(1), 85–91 (1995). doi:10.1210/jcem.80.1.7829644 PubMed

Title: Safety of transsphenoidal microsurgical approach in patients with an ACTH-secreting pituitary adenoma
Authors: Carmine Antonio Donofrio
Marco Losa
Marco Gemma
Lodoviga Giudice
Lina Raffaella Barzaghi
Pietro Mortini
Publication date: 01-11-2017
Publisher: Springer US
Published in: Endocrine / Issue 2/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-016-1214-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Safety of transsphenoidal microsurgical approach in patients with an ACTH-secreting pituitary adenoma

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2017

Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center

Osteitis fibrosa cystica—a forgotten radiological feature of primary hyperparathyroidism

Erratum to: Selenium rescues orbital fibroblasts from cell death induced by hydrogen peroxide: another molecular basis for the effects of selenium in graves’ orbitopathy

The need for national registries for rare endocrine tumor syndromes

Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database

Physical activity and hypocaloric diet recovers osteoblasts homeostasis in women affected by abdominal obesity

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page